This event is archived. Final snapshot from when the story concluded. View on Dashboard
Regulatory drug reclassification

Trump Reclassifies Marijuana to Schedule III

Analysis based on 10 articles · First reported Dec 18, 2025 · Last updated Dec 18, 2025

Sentiment
40
Attention
6
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The reclassification of marijuana is expected to significantly reduce the tax burden on the cannabis industry, potentially boosting profitability and investment in the sector. It also opens new avenues for medical research, which could benefit pharmaceutical and healthcare companies involved in cannabis-derived products.

Cannabis Pharmaceuticals Healthcare

President Donald Trump signed an executive order to reclassify marijuana from a Schedule I to a Schedule III drug, a move that aligns federal policy closer to many states' approaches. This reclassification, which the United States — Drug Enforcement Administration is expected to expedite, will not legalize recreational use nationwide but will change how the drug is regulated and reduce the tax burden on the cannabis industry. The order also calls for expanded research and access to CBD. While Donald Trump received support from some, many United States — Republican Party (United States) senators, led by Ted Budd, opposed the change, arguing it would undermine efforts to 'Make America Great Again' and benefit entities like China. This action follows a similar proposal by Joe Biden's United States — United States Department of Justice. Polling from Gallup indicates growing public support for less restrictive marijuana policies. The United States — Food and Drug Administration has found scientific support for marijuana's medical uses, and a new United States — Medicare program, announced by Mehmet Oz of the United States — Centers for Medicare & Medicaid Services, will allow older adults access to CBD. Opponents like Smart Approaches to Marijuana have vowed to sue if the reclassification proceeds.

per
Ted Budd led a group of United States — Republican Party (United States) senators in signing a letter urging Donald Trump to keep marijuana as a Schedule I drug.
Importance 40.0 Sentiment -10.0
ngo
Smart Approaches to Marijuana, an opponent group, vowed to sue if the reclassification of marijuana goes through.
Importance 20.0 Sentiment -20.0
priv
Importance 0.0 Sentiment 0.0
govactor
per
Importance 0.0 Sentiment 0.0
govactor
govactor
Importance 0.0 Sentiment 0.0
per
Importance 0.0 Sentiment 0.0
govactor
Importance 0.0 Sentiment 0.0
cnt
Importance 0.0 Sentiment 0.0
govactor
cnt
Importance 0.0 Sentiment 0.0
per
Importance 0.0 Sentiment 0.0
polparty
cnt
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.